About Aquinox Pharmaceuticals (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.
Industry, Sector and Symbol:
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: NASDAQ:AQXP
- CUSIP: N/A
- Web: aqxpharma.com
- Current Ratio: 17.25%
- Quick Ratio: 17.25%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $6.18 per share
- Price / Book: 1.71
- Trailing EPS: ($1.93)
- Net Income: $-37,000,000.00
- Return on Equity: -34.72%
- Return on Assets: -32.69%
- Employees: 38
- Outstanding Shares: 23,470,000
Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
How were Aquinox Pharmaceuticals' earnings last quarter?
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) released its earnings results on Tuesday, May, 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.15. During the same quarter last year, the business earned ($0.39) EPS. View Aquinox Pharmaceuticals' Earnings History.
Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?
3 brokers have issued twelve-month target prices for Aquinox Pharmaceuticals' shares. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $25.00 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.
What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:
- 1. Needham & Company LLC analysts commented, "Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY." (11/9/2017)
- 2. Cantor Fitzgerald analysts commented, "FDA advisory committee meeting could shed light on FDA views of IC/BPS. On December 7, the FDA will hold an advisory panel (details here) to discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs" to treat the condition. We believe the meeting could be important to raise awareness of the condition and establish expectations for how IC/BPS drugs should be developed." (11/9/2017)
- 3. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (10/10/2017)
Are investors shorting Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals saw a drop in short interest in the month of October. As of October 13th, there was short interest totalling 573,008 shares, a drop of 20.6% from the September 29th total of 721,680 shares. Based on an average trading volume of 49,508 shares, the days-to-cover ratio is currently 11.6 days. Approximately 2.5% of the shares of the stock are sold short.
Who are some of Aquinox Pharmaceuticals' key competitors?
Some companies that are related to Aquinox Pharmaceuticals include AMAG Pharmaceuticals (AMAG), Corium International (CORI), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Neos Therapeutics (NEOS), Marinus Pharmaceuticals (MRNS), Celsius Holdings (CELH), Allergy Therapeutics plc (AGY), Teligent (TLGT), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL), BioLife Solutions (BLFS), Innocoll Holdings PLC (INNL), Sophiris Bio (SPHS), Female Health Company (The) (VERU) and Juniper Pharmaceuticals (JNP).
Who are Aquinox Pharmaceuticals' key executives?
Aquinox Pharmaceuticals' management team includes the folowing people:
- David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board (Age 50)
- Kamran Alam, Chief Financial Officer, Vice President - Finance (Age 40)
- Lloyd Mackenzie, Vice President - Technical Operations and Planning (Age 47)
- David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance (Age 59)
- Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development (Age 48)
- Robert E. Pelzer, Lead Independent Director (Age 63)
- Gary J. Bridger Ph.D., Director (Age 52)
- Daniel J. Levitt M.D., Ph.D., Director (Age 68)
- Richard S. Levy M.D., Director (Age 59)
- Kelvin M. Neu M.D., Director (Age 42)
Who owns Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (1.20%), University of Notre Dame DU Lac (0.81%), Sphera Funds Management LTD. (0.32%), Citadel Advisors LLC (0.06%) and Investment Centers of America Inc. (0.05%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker and David Main. View Institutional Ownership Trends for Aquinox Pharmaceuticals.
Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including University of Notre Dame DU Lac, Citadel Advisors LLC, Sphera Funds Management LTD., Investment Centers of America Inc. and Alyeska Investment Group L.P.. View Insider Buying and Selling for Aquinox Pharmaceuticals.
How do I buy Aquinox Pharmaceuticals stock?
Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquinox Pharmaceuticals' stock price today?
One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $10.56.
How big of a company is Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals has a market capitalization of $247.79 million. The company earns $-37,000,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Aquinox Pharmaceuticals employs 38 workers across the globe.
How can I contact Aquinox Pharmaceuticals?
Aquinox Pharmaceuticals' mailing address is 887 Great Northern Way Suite 450, VANCOUVER, BC V5T 4T5, Canada. The company can be reached via phone at +1-604-6299223 or via email at [email protected]
MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aquinox Pharmaceuticals (NASDAQ:AQXP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$25.00 (136.74% upside)|
Consensus Price Target History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
(Data available from 11/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/21/2017||Canaccord Genuity||Reiterated Rating||Buy||$22.00||N/A|
|11/9/2017||Needham & Company LLC||Reiterated Rating||Buy||$25.00||N/A|
|11/9/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$28.00||N/A|
|11/11/2016||Leerink Swann||Reiterated Rating||Buy||$24.00||N/A|
|8/5/2016||Jefferies Group LLC||Boost Price Target||Hold||$7.00 -> $9.00||N/A|
Earnings History and Estimates Chart for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
2017 EPS Consensus Estimate: ($2.43)
2018 EPS Consensus Estimate: ($2.53)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ AQXP)
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 95.51%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/5/2017||David Main||Insider||Sell||15,625||$13.26||$207,187.50|| |
|1/9/2017||Bros. Advisors Lp Baker||Major Shareholder||Buy||398,062||$17.18||$6,838,705.16|| |
|9/20/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||2,783,605||$12.25||$34,099,161.25|| |
|3/16/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||471,667||$7.99||$3,768,619.33|| |
|3/15/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||109,912||$7.98||$877,097.76|| |
|1/26/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||140,786||$10.80||$1,520,488.80|| |
|1/20/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||112,034||$9.48||$1,062,082.32|| |
|1/19/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||78,045||$9.11||$710,989.95|| |
|1/15/2016||Bros. Advisors Lp Baker||Major Shareholder||Buy||202,623||$8.28||$1,677,718.44|| |
|9/10/2015||Bros. Advisors Lp Baker||Major Shareholder||Buy||2,480,032||$15.50||$38,440,496.00|| |
|8/24/2015||David Chilton Mitchell||VP||Buy||3,575||$17.81||$63,670.75|| |
|8/12/2015||Kamran Alam||CFO||Sell||29,079||$18.67||$542,904.93|| |
|8/12/2015||Lloyd Mackenzie||VP||Sell||35,887||$18.67||$670,010.29|| |
|12/17/2014||& Johnson Johnson||Major Shareholder||Sell||8,100||$7.62||$61,722.00|| |
|12/12/2014||& Johnson Johnson||Major Shareholder||Sell||5,000||$7.51||$37,550.00|| |
|12/10/2014||& Johnson Johnson||Major Shareholder||Sell||8,300||$7.72||$64,076.00|| |
|12/9/2014||& Johnson Johnson||Major Shareholder||Sell||5,000||$7.73||$38,650.00|| |
|12/8/2014||& Johnson Johnson||Major Shareholder||Sell||2,000||$7.69||$15,380.00|| |
|12/5/2014||& Johnson Johnson||Major Shareholder||Sell||15,900||$7.76||$123,384.00|| |
|12/1/2014||& Johnson Johnson||Major Shareholder||Sell||1,200||$7.54||$9,048.00|| |
|11/26/2014||& Johnson Johnson||Major Shareholder||Sell||2,000||$7.75||$15,500.00|| |
|11/24/2014||& Johnson Johnson||Major Shareholder||Sell||9,500||$8.14||$77,330.00|| |
|3/12/2014||Pfizer Inc||Major Shareholder||Buy||272,727||$11.00||$2,999,997.00|| |
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ AQXP)
|Aquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord Genuity|
www.americanbankingnews.com - November 21 at 3:24 PM
|FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor Fitzgerald|
www.americanbankingnews.com - November 15 at 7:32 AM
|Leerink Swann Weighs in on Aquinox Pharmaceuticals, Inc.'s FY2017 Earnings (AQXP)|
www.americanbankingnews.com - November 13 at 3:58 AM
|Aquinox Pharmaceuticals, Inc. (AQXP) Forecasted to Post Q1 2018 Earnings of ($0.68) Per Share|
www.americanbankingnews.com - November 10 at 10:56 AM
|Aquinox Pharmaceuticals' (AQXP) Buy Rating Reiterated at Needham & Company LLC|
www.americanbankingnews.com - November 9 at 3:42 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Receives Buy Rating from Cantor Fitzgerald|
www.americanbankingnews.com - November 9 at 10:54 AM
|Aquinox reports 3Q loss|
finance.yahoo.com - November 8 at 6:10 PM
| Analysts Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) Will Post Earnings of -$0.62 Per Share|
www.americanbankingnews.com - November 7 at 5:30 AM
|Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - November 5 at 1:42 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) to Release Earnings on Tuesday|
www.americanbankingnews.com - October 31 at 7:44 AM
|Aquinox Pharmaceuticals Inc (AQXP) Sees Significant Decrease in Short Interest|
www.americanbankingnews.com - October 29 at 1:50 AM
|Oversold Conditions For Aquinox Pharmaceuticals (AQXP)|
www.thestreet.com - October 19 at 4:35 PM
|Zacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Announce -$0.62 EPS|
www.americanbankingnews.com - October 18 at 2:24 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - October 11 at 4:42 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Sell"|
www.americanbankingnews.com - October 10 at 5:46 PM
|Innoviva (INVA) & Aquinox Pharmaceuticals (AQXP) Head-To-Head Review|
www.americanbankingnews.com - October 10 at 2:16 PM
|Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 18 at 4:25 PM
|Reviewing Aquinox Pharmaceuticals (AQXP) & Its Peers|
www.americanbankingnews.com - September 18 at 4:28 AM
|Aquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - September 16 at 4:54 PM
|Aquinox Pharmaceuticals: Buy, Sell Or Hold? - Seeking Alpha|
seekingalpha.com - September 1 at 9:35 PM
|Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome - GlobeNewswire (press release)|
globenewswire.com - August 29 at 9:24 PM
|Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome|
www.streetinsider.com - August 29 at 2:07 AM
|Collegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP) Head-To-Head Comparison|
www.americanbankingnews.com - August 29 at 12:22 AM
|Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder ... - StreetInsider.com|
www.streetinsider.com - August 28 at 9:07 PM
|Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome|
feeds.benzinga.com - August 28 at 9:46 AM
|Aquinox Pharmaceuticals, Inc. (AQXP) Expected to Post Earnings of -$0.62 Per Share|
www.americanbankingnews.com - August 23 at 12:20 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - August 22 at 4:36 PM
|Dr. Reddy's Laboratories (RDY) versus Aquinox Pharmaceuticals (AQXP) Head-To-Head Contrast|
www.americanbankingnews.com - August 22 at 4:16 PM
|Analyzing the Financial Health of Biotech Companies - PR Newswire (press release)|
www.prnewswire.com - August 17 at 10:27 PM
|FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by Analyst|
www.americanbankingnews.com - August 10 at 1:50 PM
|Aquinox Pharmaceuticals' (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - August 8 at 3:52 PM
|Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)|
globenewswire.com - August 8 at 3:52 PM
|Investor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call|
finance.yahoo.com - August 8 at 3:52 PM
|Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results|
finance.yahoo.com - August 8 at 3:51 PM
|Aquinox reports 2Q loss|
finance.yahoo.com - August 8 at 3:51 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Issues Earnings Results|
www.americanbankingnews.com - August 8 at 2:24 PM
|Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference|
finance.yahoo.com - August 2 at 4:50 PM
|Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference|
finance.yahoo.com - August 2 at 4:50 PM
|Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results|
finance.yahoo.com - August 1 at 4:59 PM
|Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - July 28 at 4:39 PM
|Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on Wednesday|
www.americanbankingnews.com - July 26 at 7:20 AM
|Analyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT)|
www.americanbankingnews.com - July 19 at 8:51 AM
| Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share|
www.americanbankingnews.com - July 13 at 10:20 PM
|Corium International (CORI) Catches Eye: Stock Jumps 11.9%|
finance.yahoo.com - July 8 at 6:21 AM
|Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - July 3 at 4:58 PM
|BRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36|
www.reuters.com - May 11 at 3:59 PM
|Aquinox Pharma (AQXP) Names Kelvin Neu and Richard Levy to Board of Directors|
www.streetinsider.com - March 28 at 10:31 AM
|AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and|
biz.yahoo.com - March 28 at 10:31 AM
|Aquinox Pharmaceuticals (AQXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow|
seekingalpha.com - March 22 at 9:08 PM
|AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - March 16 at 5:06 PM
Aquinox Pharmaceuticals (NASDAQ AQXP) Chart for Tuesday, November, 21, 2017